MAYO CLINIC
Q4 2022 Form 13-F

ROCHESTER, MINNESOTA
CIK 0001318153 · Institutional investment manager
$188.8M Reported Value Total
Reported value
$188.8M
Quarter over quarter
+13.2%
Holdings
13
Top-10 concentration
100.0%

Key People

Named on the latest Form 13-F filing — not necessarily an owner
Paul A Gorman
Chief Investment Officer

Filing Navigation

13F Metrics

Loading 13F Metrics

Q4 2022 13F record

Q4 2022 13F filing summary

Q4 2022 Form 13F portfolio summary
Period of report December 31, 2022
Filed January 26, 2023
Form 13F-HR
Reported value $188.8M
Positions 13
Change in reported value +108.8%
New positions 4
Exited positions 0
Position turnover 30.8%
Top-10 concentration 100.0%

13F filings by quarter

Form 13F filings by quarter
Quarter Positions Value
Q3 2024 13F
Filed Nov 12, 2024
3 $2.9M
Q2 2024 13F
Filed Aug 12, 2024
4 $3.0M
Q1 2024 13F
Filed May 13, 2024
5 $6.1M
Q4 2023 13F
Filed Feb 13, 2024
7 $16.2M
Q3 2023 13F
Filed Nov 14, 2023
9 $51.9M
Q2 2023 13F
Filed Aug 9, 2023
11 $97.4M
Q1 2023 13F
Filed May 5, 2023
13 $121.8M
Q4 2022 13F
Filed Jan 26, 2023
13 $188.8M
Q2 2021 13F
Filed Aug 12, 2021
9 $90.4M
Q1 2021 13F
Filed May 13, 2021
8 $86.9M
Q4 2020 13F
Filed Feb 11, 2021
9 $83.1M
Q3 2020 13F
Filed Nov 12, 2020
9 $74.2M
Q2 2020 13F
Filed Aug 13, 2020
8 $104.5M
Q1 2020 13F
Filed Apr 24, 2020
7 $39.5M
Q4 2019 13F
Filed Feb 12, 2020
8 $88.2M

Top 13 holdings · Q4 2022

Largest Q4 2022 13F positions by reported value
# Holding Reported value % of portfolio
1 ACWI MSCI ACWI ETF $169.1M 89.58%
2 BSM BLACK STONE MINERALS $10.9M 5.75%
3 ZNTL Zentalis Pharmaceuticals Inc $6.0M 3.17%
4 EVLO EVELO BIOSCIENCES INC $771.6K 0.41%
5 MIRO Miromatrix Med Inc $573.0K 0.3%
6 UBX UNITY BIOTECHNOLOGY INC $430.7K 0.23%
7 CLPT Clearpoint Neuro Inc $322.8K 0.17%
8 SRNEQ Sorento Therapeutics $267.0K 0.14%
9 NMTC Neuroon Medical Technologies $218.1K 0.12%
10 EXAS Exact Sciences $181.0K 0.1%
11 BSGM BIOSIG TECH INC $42.4K 0.02%
12 VYNT Vyant Bio Inc $19.4K 0.01%
13 TDOC Teladoc Health Inc Com $15.6K < 0.01%

Values as reported on the Q4 2022 Form 13F. Every position is in the holdings table below.

Filing Details

Loading Activities
Loading Sector Allocation
Crunching numbers

Performance

Loading Performance

Potential New Buys

Finding Potential New Buys

Holdings

Building table
Loading SEC filing data
Loading Form 4 Filings

Beneficial Ownership (Schedule 13D/13G)

Loading 13D/G filings